OBJECTIVE: The death receptor Fas is a critical mediator of the extrinsic apoptotic pathway, and its role in mediating lymphoproliferation has been extensively examined. The present study was undertaken to investigate the impact of myeloid cell-specific loss of Fas. METHODS: Mice with Fas flanked by loxP sites (Fas(flox/flox) ) were crossed with mice expressing Cre under control of the murine lysozyme M gene promoter (Cre(LysM) ), which functions in mature lysozyme-expressing cells of the myelomonocytic lineage. The genotype for Cre(LysM) Fas(flox/flox) mice was verified by polymerase chain reaction and flow cytometric analysis. Flow cytometric analysis was also used to characterize myeloid, dendritic, and lymphoid cell distribution and activation in bone marrow, blood, and spleen. Luminex-based assays and enzyme-linked immunosorbent assays were used to measure serum cytokine/chemokine and immunoglobulin levels. Renal damage or dysfunction was examined by immunohistochemical and immunofluorescence analysis. RESULTS: Cre(LysM) Fas(flox/flox) mice exhibited a systemic lupus erythematosus (SLE)-like disease that included leukocytosis, splenomegaly, hypergammaglobulinemia, antinuclear autoantibody and proinflammatory cytokine production, and glomerulonephritis. Loss of Fas in myeloid cells increased levels of both Gr-1(low) and Gr-1(intermediate) blood monocytes and splenic macrophages and, in a paracrine manner, incited activation of conventional dendritic cells and lymphocytes in Cre(LysM) Fas(flox/flox) mice. CONCLUSION: Taken together, these results suggest that loss of Fas in myeloid cells is sufficient to induce inflammatory phenotypes in mice, reminiscent of an SLE-like disease. Thus, Fas in myeloid cells may be considered a suppressor of systemic autoimmunity.
OBJECTIVE: The death receptor Fas is a critical mediator of the extrinsic apoptotic pathway, and its role in mediating lymphoproliferation has been extensively examined. The present study was undertaken to investigate the impact of myeloid cell-specific loss of Fas. METHODS:Mice with Fas flanked by loxP sites (Fas(flox/flox) ) were crossed with mice expressing Cre under control of the murine lysozyme M gene promoter (Cre(LysM) ), which functions in mature lysozyme-expressing cells of the myelomonocytic lineage. The genotype for Cre(LysM) Fas(flox/flox) mice was verified by polymerase chain reaction and flow cytometric analysis. Flow cytometric analysis was also used to characterize myeloid, dendritic, and lymphoid cell distribution and activation in bone marrow, blood, and spleen. Luminex-based assays and enzyme-linked immunosorbent assays were used to measure serum cytokine/chemokine and immunoglobulin levels. Renal damage or dysfunction was examined by immunohistochemical and immunofluorescence analysis. RESULTS: Cre(LysM) Fas(flox/flox) mice exhibited a systemic lupus erythematosus (SLE)-like disease that included leukocytosis, splenomegaly, hypergammaglobulinemia, antinuclear autoantibody and proinflammatory cytokine production, and glomerulonephritis. Loss of Fas in myeloid cells increased levels of both Gr-1(low) and Gr-1(intermediate) blood monocytes and splenic macrophages and, in a paracrine manner, incited activation of conventional dendritic cells and lymphocytes in Cre(LysM) Fas(flox/flox) mice. CONCLUSION: Taken together, these results suggest that loss of Fas in myeloid cells is sufficient to induce inflammatory phenotypes in mice, reminiscent of an SLE-like disease. Thus, Fas in myeloid cells may be considered a suppressor of systemic autoimmunity.
Authors: Jack Hutcheson; John C Scatizzi; Akbar M Siddiqui; G Kenneth Haines; Tianfu Wu; Quan-Zhen Li; Laurie S Davis; Chandra Mohan; Harris Perlman Journal: Immunity Date: 2008-02 Impact factor: 31.745
Authors: Zhenyue Hao; Gordon S Duncan; Jane Seagal; Yu-Wen Su; Claire Hong; Jillian Haight; Nien-Jung Chen; Andrew Elia; Andrew Wakeham; Wanda Y Li; Jennifer Liepa; Geoffrey A Wood; Stefano Casola; Klaus Rajewsky; Tak W Mak Journal: Immunity Date: 2008-10-02 Impact factor: 31.745
Authors: Chun Kwok Wong; Lydia Choi Wan Lit; Lai Shan Tam; Edmund Kwok Ming Li; Purple Tsz Yan Wong; Christopher Wai Kei Lam Journal: Clin Immunol Date: 2008-03-25 Impact factor: 3.969
Authors: Peter B Stranges; Jessica Watson; Cristie J Cooper; Caroline-Morgane Choisy-Rossi; Austin C Stonebraker; Ryan A Beighton; Heather Hartig; John P Sundberg; Stein Servick; Gunnar Kaufmann; Pamela J Fink; Alexander V Chervonsky Journal: Immunity Date: 2007-05 Impact factor: 31.745
Authors: Jason W Bauer; Emily C Baechler; Michelle Petri; Franak M Batliwalla; Dianna Crawford; Ward A Ortmann; Karl J Espe; Wentian Li; Dhavalkumar D Patel; Peter K Gregersen; Timothy W Behrens Journal: PLoS Med Date: 2006-12 Impact factor: 11.069
Authors: Yanjun Feng; Devon Livingston-Rosanoff; Linda Roback; Aarthi Sundararajan; Samuel H Speck; Edward S Mocarski; Lisa P Daley-Bauer Journal: J Immunol Date: 2018-09-07 Impact factor: 5.422
Authors: Carla M Cuda; Alexander V Misharin; Angelica K Gierut; Rana Saber; G Kenneth Haines; Jack Hutcheson; Stephen M Hedrick; Chandra Mohan; G Scott Budinger; Christian Stehlik; Harris Perlman Journal: J Immunol Date: 2014-05-07 Impact factor: 5.422
Authors: Qi-Quan Huang; Robert Birkett; Renee E Koessler; Carla M Cuda; G Kenneth Haines; Jian-Ping Jin; Harris Perlman; Richard M Pope Journal: Arthritis Rheumatol Date: 2014-01 Impact factor: 10.995
Authors: Carla M Cuda; Alexander V Misharin; Sonal Khare; Rana Saber; FuNien Tsai; Amy M Archer; Philip J Homan; G Kenneth Haines; Jack Hutcheson; Andrea Dorfleutner; G R Scott Budinger; Christian Stehlik; Harris Perlman Journal: Arthritis Res Ther Date: 2015-10-16 Impact factor: 5.156